The year 2017 was a big year for the world of pharmaceuticals, and it was also a year of bad news for the pharmaceutical industry as a whole.
Pharmaceuticals suffered a slew of scandals over the past decade, including an explosion of deadly opioid prescriptions and a major rise in prescription drug overdoses.
In the process, the industry also became the focus of a series of investigations into its business practices.
One of the biggest scandals, however, was the way Pfizer’s $15 billion purchase of AstraZeneca in 2015 turned out to be an illegal deal.
Pfizer was caught breaking the law by paying less than its fair share for the rights to sell AstraZeneca’s drug, but the company was never prosecuted.
The company, like other pharmaceutical companies, has struggled financially over the years, as a result of declining sales, rising prescription drug prices, and other problems.
But it has also become one of the most popular brands in the world.
The drug maker’s stock price surged as high as $3,300 per share in 2017.
Now, the company is on a bit of a tear.
The stock has risen nearly 20% since the beginning of 2017, thanks in part to Pfizer paying a $3 billion premium on the stock.
And, just like last year, there are several new drugs coming out in the pipeline.
These drugs are all being developed by companies like Astra Zeneca, and some of them will have a big impact on the lives of people in the US and abroad.
But if you think about it, Pfizer is just one of a number of pharmaceutical companies that have turned to new technology to make money.
That means it has a lot of potential to be a huge success story in the future.
How Pfizer Became a Drugmaker When Pfizer acquired Astra in 2015, it became the biggest pharmaceutical company in the country, with over 100 different drugs on the market.
That is a lot for a company with a small workforce of just three people.
But, unlike other pharmaceuticals that have relied on acquisitions to get into the market, Pfizner didn’t have to make a big investment in its new business.
Instead, the $3.5 billion purchase was a strategic move to become a major player in the global medical supply chain.
Pfizners executives saw the pharmaceutical market as the biggest opportunity in the 21st century, and they wanted to take advantage of it.
Pfiza is a big business, but it isn’t the only one Pfizer has built.
In addition to the Astra acquisition, Pfizers recently bought a number, including a company called Pfizer Inc. that sells an antiseptic medication called Zyrtec, which is used to treat a number different types of cancer.
Pfizehn has also been trying to sell its own drugs.
But none of those companies are likely to have the same success as Pfizons.
Pfazers newest drug, Pfiza, was developed with a large team of pharmaceutical experts in mind.
It is a small drug, about a half-gram in weight, but its effects are huge, according to the company.
In fact, it has been shown to be nearly as effective as the brand name of another drug, Prozac, according the Journal of the American Medical Association.
And it has some other promising effects too.
Pfozers scientists are working on the drug as well as creating the first human trials to prove that it works in animals.
The results could help doctors better design and treat patients.
Pfiazner has also launched a new type of drug called Pfizynt, which has also had some promising results.
These new drugs have been developed to treat the common cold, and the company hopes to have a ready-to-use version of them on the shelves by the end of the year.
But Pfizion also has a very lucrative business in the health care space, with its own specialty drug, Astra, that it uses to treat heart disease and other common ailments.
And Pfizers new drug has also shown promise in other areas as well.
Its drugs are effective against several types of cancers, including ovarian, lung, and pancreatic, and Pfizys new drug, called Pfiza-R, has been found to be as effective against breast cancer as it is for prostate cancer.
But the drug is currently under development.
PfIZs biggest competitor is not even a drugmaker, but an offshoot of the pharmaceutical sector called pharmaceutical research and development, or PhR&D.
PhR is a new field of research that uses the latest scientific knowledge in the pharmaceutical and health care industries to develop drugs and treatments.
Pfizers PhR &D team includes a lot more than just Pfizones drugs.
It includes companies like Bristol-Myers Squibb, Novartis, and Astrazeneca.
Pfuzies drug, however will be its first to